NCT00310206View on ClinicalTrials.gov

H5N1 Vaccine Intramuscular Versus Intradermal in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

October 31, 2006

Study Completion Date

October 31, 2006

Conditions
Influenza
Interventions
BIOLOGICAL

Inactivated Influenza A Vaccine A/H5N1

Monovalent subvirion H5 vaccine (HA of A/Vietnam/1203/04), inactivated A/H5N1 vaccine administered intradermally (ID); doses: 3 or 9 micrograms.

BIOLOGICAL

Inactivated Influenza A Vaccine A/H5N1

Monovalent subvirion H5 vaccine (HA of A/Vietnam/1203/04), inactivated A/H5N1 vaccine administered intramuscularly (IM); doses: 15 or 45 micrograms.

Trial Locations (1)

77030

Baylor College of Medicine, Houston

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00310206 - H5N1 Vaccine Intramuscular Versus Intradermal in Healthy Adults | Biotech Hunter | Biotech Hunter